Strategies to augment adherence in the management of sleep-disordered breathing. by Sunwoo, Bernie Y et al.
UC San Diego
UC San Diego Previously Published Works
Title
Strategies to augment adherence in the management of sleep-disordered breathing.
Permalink
https://escholarship.org/uc/item/9rd7p2x5
Authors
Sunwoo, Bernie Y
Light, Matthew
Malhotra, Atul
Publication Date
2019-07-03
DOI
10.1111/resp.13589
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
INVITED REVIEW SERIES:
NEW FRONTIERS IN SLEEP-DISORDERED BREATHING
SERIES EDITORS: MATTHEW NAUGHTON, PETER A. CISTULLI AND PHILIP DE CHAZAL
Strategies to augment adherence in the management
of sleep-disordered breathing
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Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego,
CA, USA
ABSTRACT
Continuous positive airway pressure (CPAP) is highly
effective in treating sleep-disordered breathing (SDB).
However, unlike surgical interventions, this treatment
modality relies heavily on patient acceptance and adher-
ence. The current deﬁnition of adherence is largely arbi-
trary and is mainly used by third-party payers to
determine CPAP reimbursement but CPAP adherence
remains sub-optimal. Strategies to augment adherence,
especially early in the course of a CPAP trial, are needed
in the management of SDB. An understanding of the
basis for observed differences in CPAP and oral appli-
ance (OA) use is necessary in developing these strategies,
but to date no single factor has been consistently identi-
ﬁed. Consequently, a multidimensional approach using
educational, behavioural, technological and potentially
pharmacological strategies to target (i) disease character-
istics, (ii) patient characteristics including psychosocial
factors, (iii) treatment protocols and (iv) technological
devices and side effects that may inﬂuence adherence, is
likely required to augment the complex behaviour of
CPAP and OA use. In the near future, we envision a per-
sonalized medicine approach to determine the risk of
non-adherence and set individualized adherence goals
aimed at treating speciﬁc symptoms (e.g. excessive day-
time sleepiness) and reducing the risk of patient-speciﬁc
SDB consequences (e.g. atherosclerosis). Resources for
interventions to improve adherence such as educational
programmes and telemedicine encounters could then be
more efﬁciently allocated.
Key words: compliance, continuous positive airway pressure
adherence, lung, sleep apnoea, sleep-disordered breathing.
INTRODUCTION
Sleep-disordered breathing (SDB) is highly prevalent
and associated with considerable morbidity and mor-
tality. Positive airway pressure (PAP) is currently the
mainstay of treatment, but unlike surgical interven-
tions, efﬁcacy relies heavily on acceptance and adher-
ence. The stakes are high; on an individual level, SDB
results in a number of disease consequences including
cardiovascular and metabolic disease. From a societal
perspective, excessive daytime sleepiness and impaired
functioning during wakefulness have profound socio-
economic implications.
DEFINING ADHERENCE TO THERAPY
While somewhat arbitrary, a threshold of less than 4 h
of nightly PAP use on 70% of nights has been adopted
to deﬁne non-adherence. This threshold has been
debated since a dose–response relationship between
PAP usage and clinical outcomes in obstructive sleep
apnoea (OSA) has been demonstrated.1–4 That being
said, speciﬁc adherence thresholds to treat OSA conse-
quences are moving targets and vary depending on the
outcomes of interest. In a cohort of 149 patients with
severe OSA, Weaver et al. demonstrated that 4 h of
nightly continuous PAP (CPAP) use was associated
with improvement in the Epworth Sleepiness Scale but
7.5 h of nightly use was required for improvement in
the Multiple Sleep Latency Test and Functional Out-
comes associated with Sleepiness Questionnaire.1 For
treatment of hypertension, CPAP usage >3.5 h was
associated with greater reduction in 24-h diastolic
blood pressure after 4 weeks of treatment.5 There is,
however, general acknowledgement that more is better
with respect to CPAP usage.
In the USA, this concept of an adherence threshold
has not been helped by third-party payers who have
developed strict criteria for PAP reimbursement man-
dating the use of PAP adherence tracking systems. The
Centers for Medicare and Medicaid Services (CMS)
requires that for continued PAP coverage beyond the
ﬁrst 3 months of therapy, the treating physician must
conduct a face-to-face clinical re-evaluation no sooner
than 31 days but no later than 91 days after initiating
therapy. In addition, there must be documentation that
the patient is beneﬁting from PAP therapy with objec-
tive evidence of PAP adherence based on download
data showing ≥4 h of nightly use for ≥70% of nights
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monitored during a consecutive 30-day period. These
criteria reinforce the erroneous notion of a therapeutic
threshold and do not take into consideration the evi-
dence suggesting that some PAP use is better than no
use. In an outpatient cohort of 227 patients with concur-
rent chronic obstructive pulmonary disease and OSA or
the overlap syndrome, any level of CPAP use was associ-
ated with some mortality beneﬁt over no CPAP use.6
ADHERENCE ESTIMATES, SELF-
REPORTING AND OBJECTIVE USAGE
MEASUREMENTS
Adherence, the main limitation to PAP therapy, is
highly variable but remains sub-optimal in many
patient populations. Using a criterion of 4 h or less of
nightly use, CPAP non-adherence has been estimated
between 29% and 83%.3,7,8 We have recently observed
evidence of improving adherence over time, with one
Big Data analysis showing up to 87% adherence using
modern technology.9 The pattern of PAP usage is
established early, typically during the ﬁrst week of ther-
apy, and has been shown to predict long-term
use.3,4,10–12 Compared with PAP, oral appliance
(OA) adherence is usually higher but is also highly vari-
able with 1-year compliance estimates between 32%
and 82%. Comparison of the two modalities is limited,
however, as the majority of studies compare subjective
reports of OA use with objective CPAP usage data.13–16
In the past, the accuracy of PAP adherence estimates
has been limited by self-reporting, which was often
unreliable. This situation has changed as device tech-
nology now allows for objective measurement of use.
Microprocessors embedded within PAP units monitor
cumulative time that the PAP device is turned on at the
effective pressure. While this technology is not yet able
to discriminate who is wearing the device when turned
on, it does reliably track PAP use.17 This information
can then be viewed using various transmission systems
including smartcards or SD cards, memory sticks and
via modem or wireless transmission. The information
is not standardized between the different proprietary
tracking systems but adherence data are available for
all (Fig. 1). Of note, self-reported PAP use overesti-
mates actual use (as determined by machine down-
load) by approximately 1 h.3,18 A meta-analysis of
11 randomized controlled trials found that mean sub-
jective CPAP use time was 0.70 (95% CI: 0.11–1.30)
more hours per night than objective measures among
treated OSA patients.14 Like CPAP, efﬁcacy of mandibu-
lar advancement devices (MAD) is also reliant on
adherence, and although there appears to be less
reporting bias than with PAP, treatment tracking sys-
tems are being developed to limit discrepancies. An
MAD with a built-in thermal sensor was studied in
80 patients with varying OSA severity.19 In this study,
sensor-reported use was shown to be consistent with
self-reported use. Meanwhile, Castillo et al. integrated
a tooth microphone with an oral appliance device and
monitored adherence through audio recording of
night-time respiratory sounds.20 Whether such efforts
to monitor use objectively alters adherence remains
unclear.
AUGMENTING ADHERENCE
Given the challenges with adherence, strategies to aug-
ment adherence are needed in the management of
SDB. Investigators have mainly focused on identifying
and targeting factors that may predict or inﬂuence
adherence. An understanding of the basis for observed
differences in PAP and OA use is necessary in develop-
ing strategies to improve adherence. Yet, to date, no
single factor has been consistently identiﬁed, and com-
monly explored anthropometric, symptomatic or polys-
omnographic severity was found to explain just 4–25%
of variance in CPAP use.21 Consequently, a multi-
dimensional approach using educational, behavioural,
technological and potentially pharmacological strate-
gies to target (i) disease characteristics, (ii) patient
characteristics including psychosocial factors,
(iii) treatment protocols and (iv) technological devices
and side effects that may inﬂuence adherence, is likely
required to augment the complex behaviour of PAP
and OA use.7
Disease characteristics
SDB characteristics are not likely to be modiﬁable tar-
gets to improve adherence. OSA severity, typically mea-
sured using the apnoea–hypopnoea index, has not
been consistently identiﬁed as a predictor of CPAP
adherence.3,11,12,22,23 Similarly, studies looking at the
association between REM-related OSA and CPAP
adherence have been mixed.24,25 A more convincing
association has been observed between initial severity
of daytime sleepiness and PAP use, and an Epworth
Sleepiness score > 10 was shown to be an independent
predictor of long-term CPAP use in 1211 consecutive
OSA patients.3,12 Patients with the greatest level of
CPAP adherence typically report the greatest improve-
ment in OSA symptoms including daytime energy and
greater satisfaction with CPAP use, but in a possible
bidirectional relationship this improvement in OSA
symptoms has also been shown to correlate positively
with CPAP use.26
Patient characteristics
Anthropometric variables including age, sex and mari-
tal status have not been consistently associated with
CPAP adherence nor are they readily modiﬁable strate-
gic targets to improve adherence.8 Some (but not all)
studies have suggested worse CPAP adherence in
African-Americans,27–30 although reasons for this dis-
parity are unclear, but may be a function primarily of
socio-economic status. Very little data exist for other
races and there is a need for future research on CPAP
adherence among different demographics, including
women, older patients and in different ethnic groups.
In a sample of 126 New Zealand patients with OSA ini-
tiating CPAP therapy, 19.8% were Mãori. This group
had signiﬁcantly lower CPAP usage than non-Mãori
but in a multiple regression model including ethnicity,
socio-economic status, annual income, level of formal
education and eligibility for government-subsidized
health care, only non-completion of tertiary education
and socio-economic deprivation remained as
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signiﬁcant independent predictors of CPAP non-adher-
ence.31 In a retrospective cohort of 260 veterans with
newly diagnosed OSA, initial CPAP adherence was
closely associated with higher neighbourhood socio-
economic factors.32 After adjustment for individual
socio-demographic characteristics and medical co-
morbidity, the probability of daily CPAP use of 4 h
ranged from 34.1% (95% CI: 26.4–42.7) for subjects
from a low socio-economic neighbourhood to 62.3%
(95% CI: 53.8–70.1) for subjects from a high socio-
economic neighbourhood. CPAP users have been
shown to have more years of education and be more
likely to work in professional occupations.3 To this
extent, a social history may be helpful in developing a
successful strategy to improve PAP and OA adherence.
Both PAP and OA adherence have been shown to be
associated with psychological traits and disposition.
The Type D (distressed) personality, deﬁned as a com-
bination of negative affectivity and social inhibition,
was found in 30% of 247 OSA patients treated with
CPAP for longer than 60 months. This personality type
signiﬁcantly increased the perceived frequency and
severity of a range of side effects and had lower objec-
tive CPAP adherence compared to patients without
Type D personality.33 Type D personality patients also
reported a signiﬁcantly higher discontinuation rate
using MAD when compared to patients without Type D
personality.34 The authors argued that identiﬁcation of
this personality could be used by healthcare personnel
when evaluating patients awaiting treatment.
CPAP use has been associated with a patient’s per-
ception of OSA symptoms and risks of SDB as well as
perceived beneﬁts to therapy. CPAP use may also relate
to treatment outcome expectations, self-efﬁcacy and
coping mechanisms.23 These psychological factors may
be more important than any other patient characteristic
in determining patterns of CPAP and OA use. Patients
who self-initiate their referral have been shown to have
greater CPAP use.35 Very high treatment outcome
expectations may be associated with worse adherence.
Higher self-efﬁcacy or conﬁdence in the ability to use
CPAP when faced with difﬁculties can improve adher-
ence and positive effect.36 CPAP adherence has also
been associated with engagement in active coping
strategies with new and difﬁcult situations.37
Despite the inﬂuence of these psychological factors,
depression and anxiety do not seem to inﬂuence CPAP
adherence signiﬁcantly, and no association was dem-
onstrated between the Hospital Anxiety and Depression
scale and CPAP use.38 Claustrophobia, however, may
be associated with poor adherence. A 15-item subscale
measuring claustrophobic tendencies was measured
pre-CPAP and after 3 months of CPAP in a secondary
analysis of data from a prospective study of 153 OSA
participants that completed 3 months of CPAP ther-
apy.39 Poor CPAP adherence (<2 h per night) was more
than two times higher in participants with a claustro-
phobia score of ≥25. Identiﬁcation of patients with
claustrophobic tendencies and targeted interventions
designed to reduce the fear and intrusiveness of SDB
therapies may be beneﬁcial. Our clinical experience
with modern masks including nasal pillows suggests
that claustrophobia may be less of an issue in 2018
than in the past years.
Cognitive perception has been shown to inﬂuence
PAP use, emphasizing the importance of education in
patient formulation of accurate and realistic percep-
tions and expectations, both regarding SDB and
Figure 1 Examples of data downloaded from two different positive airway pressure (PAP) units.
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treatments.7 Knowledge and support are likely of
greater importance in those with less background edu-
cation as discussed above. Patient education is recog-
nized as a standard of care in the treatment of SDB.40
Despite this recognition, studies investigating the
effects of educational strategies alone on PAP adher-
ence have been mixed and generally shown minimal
effect.41 The heterogeneity of the educational strategies
used makes generalizations difﬁcult and many do not
measure the mediating variable of knowledge. Meurice
et al. studied the effects of four educational strategies
on CPAP compliance in 112 severe OSA patients in
seven centres in the French ANTADIR homecare net-
work.42 Patients received either a simple oral explana-
tion or an oral and written explanation of CPAP use. In
addition, they received, from homecare technicians,
either a single home visit at CPAP onset, or repeated
home visits at CPAP onset and at 1 week, 1 month and
3 months after. There was no signiﬁcant difference in
adherence between all four education groups. In con-
trast, Lai et al. randomized 100 OSA patients to a brief
motivational enhancement education programme or
usual care.43 The intervention group received usual
care plus a brief motivational education programme
directed at enhancing the subjects’ knowledge, motiva-
tion and self-efﬁcacy to CPAP through the use of a
25-min video, a 20-min patient-centred interview and a
10-min telephone follow-up. The intervention group
had better CPAP use (higher daily CPAP usage by 2 h
per day (P < 0.001)) and a fourfold increase in the
number of patients using CPAP for ≥70% of days with
≥4 h/day. These studies demonstrate the differences
and frequent overlap in interventions. The equivalent
amount of education and support employed as the
control in one study may serve as the intervention in
another, limiting interpretation of educational strate-
gies on PAP adherence.8 More recently, with technolog-
ical advances, there has been interest in alternative
platforms for delivery of educational materials includ-
ing video as discussed below. Guralnick et al. random-
ized 212 patients referred to a sleep laboratory that
served a predominantly minority population for
suspected OSA to view an educational video about OSA
and CPAP therapy before the sleep study or to usual
care.44 No difference in CPAP adherence was observed
at 30 days.
Greater success has been described with cognitive
behavioural or motivational strategies in improving
adherence.35,45–51 These behavioural strategies again
recognize the psychosocial inﬂuences on PAP adher-
ence. In a meta-analysis assessing the effectiveness of
educational, supportive or behavioural strategies in
encouraging CPAP use, most studies incorporated ele-
ments of more than one intervention.48 Low- to
moderate-quality evidence showed that all three types
of interventions led to increased CPAP usage in CPAP-
naïve participants with moderate to severe OSA. Behav-
ioural therapies led to improvement in average CPAP
usage by 1.44 h/night (95% CI: 0.43–2.45, n = 584, six
studies: low-quality evidence) and increased the num-
ber of participants who used their machines for longer
than 4 h per nights from 28 to 47 per 100 (OR: 2.23,
95% CI: 1.45–3.45, n = 358, 3 studies, low-quality evi-
dence). These behavioural strategies have been shown
to have greater effect size than support or educational
interventions, but studies on behavioural strategies are
again limited by heterogeneity of interventions with
most interventions being a composite of various strate-
gies.41 Similar to educational strategies, technologies
are also being incorporated into behavioural strategies,
discussed below. Cognitive behavioural therapies may
increase CPAP use by improving self-efﬁcacy and social
support.51
Social support has been shown to have a positive
inﬂuence on adherence in a few studies.8 Lewis et al.
found CPAP use was higher in those living with some-
one as compared with those living alone.38 SDB treat-
ments may raise concerns among patients regarding
less intimacy with their bed partner and discussions
regarding these concerns may inﬂuence adherence.30
In a study assessing the impact of OSA and CPAP treat-
ment on patients’ partners, reported change in the
partners’ sleep quality between pre-sleep study and
CPAP treatment correlated positively with CPAP use
(r = 0.5, P = 0.01).52 Baron et al. also found that percep-
tion of wives’ support for CPAP treatment predicted
increased adherence, but only in patients with high
disease severity.36 Spousal pressure to use CPAP was
not found to be beneﬁcial for adherence.
In completing the biopsychosocial model and
returning to biological predictors of PAP, nasal patency
is a potential patient target to improve PAP adherence.
PAP devices rely on delivery of pressurized air via ﬂexi-
ble tubing connecting to an external mask that inter-
faces with the patient. While various types of interfaces
exist, nasal patency and resistance as measured using
various techniques including active anterior rhino-
manometry and acoustic rhinometry have been shown
to have a signiﬁcant effect on PAP adherence.53–56 CPAP
use is lower in patients with smaller nasal passages,
and nasal congestion has been associated with a
decrease in mean daily CPAP use.53,54 Addressing nasal
patency, often with the input of an otolaryngologist, is
one strategy to improve PAP adherence. If symptoms
persist despite medical therapies, surgery may be
required.57,58 Surgical correction of severe nasal
obstruction in 12 patients with severe OSA refractory to
CPAP treatment resulted in a signiﬁcant decrease in
nasal resistance and rendered all patients tolerant to
CPAP.58 In fact, some otolaryngologists have suggested
that nasal septoplasty to facilitate PAP adherence is the
most common surgery for OSA.
Treatment protocols
Early adoption of CPAP use has been associated with
long-term adherence and consequently the initial
period of CPAP prescription and initiation has been a
target of interest.8,10,12 PAP can now be introduced in-
laboratory or at home using auto-titrating PAP technol-
ogies. Several randomized trials have compared home
testing with auto-titrating PAP to traditional CPAP pre-
scription following in-laboratory diagnostic and titra-
tion polysomnography. In patients with a high pretest
probability of moderate to severe OSA without major
co-morbid medical conditions, this ambulatory model
of care can provide excellent results, comparable to the
traditional model.59–61 A meta-analysis and meta-
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regression of nine randomized trials studying a total of
282 patients found auto-titrating PAP was associated
with a reduction in the mean applied pressure across
the night by 2.2 cm H2O compared to CPAP and with
similar adherence.62 Other investigators have suggested
greater comfort and improved adherence with auto-
titrating CPAP in patients requiring CPAP levels higher
than 10 cm H2O and in patients reporting side effects
on conventional CPAP.63,64 Reporting problems after
the ﬁrst night of CPAP has been shown to be an impor-
tant predictor of ensuing CPAP use.38 In a population-
based comprehensive CPAP programme utilizing daily
telephone contact within the ﬁrst week, ‘troubleshoot-
ing’ and regular feedback to both patients and physi-
cians was shown to achieve CPAP compliance rates
>85% over 6 months, again emphasizing the potential
importance of early interventions in improving
adherence.65
Others have assessed the use of a sedative-hypnotic
early on during CPAP initiation in improving long-term
PAP adherence with mixed results.66–70 Both the
approach of using a single sedative dose, typically a Z-
hypnotic, prior to split-night or titration poly-
somnography and regular use of a sedative for the ﬁrst
14 days of CPAP therapy have been studied, but again
no consistent improvement in adherence has been
shown.
Following treatment initiation, the American Tho-
racic Society has recommended measuring outcomes
1 week, 4–6 weeks, 12 weeks, 6 months, 1 year after
and then yearly monitoring thereafter.17 However,
access to sleep providers remains limited and in reality
follow-up monitoring is, at least in the USA, heavily
inﬂuenced by third-party payers’ reimbursement
criteria for PAP and OA devices. The arbitrary
31–90-day follow-up requirement imposed by CMS for
PAP as discussed above may result in adverse conse-
quences for some patients, adding inconvenience and
expense for patients. Anecdotally, we feel that the fear
of costs related to not meeting CMS reimbursement
criteria has become a major determinant of PAP and
OA acceptance and adherence, potentially improving
adherence. Moreover, patients of disadvantaged socio-
economic status, unmarried and those with psychiatric
disease may have difﬁculty meeting these reimburse-
ment criteria, potentially resulting in unintended dis-
crimination in provision of healthcare services.71
While follow-up is necessary in ensuring treatment
adherence, the frequency, intensity and modality of
follow-up to optimize adherence remain unknown.
Adherence during the week prior to a clinic visit has
been shown to be higher than the average adherence
during the 2-month period prior to the clinic visit,
suggesting importance of regular follow-up.53 Follow-
up visits allow for identiﬁcation and troubleshooting of
treatment side effects. As discussed, studies on follow-
up are now incorporating educational and behavioural
interventions but again these interventions vary in spe-
ciﬁc constructs.
Novel technologies including smartphones are also
increasingly being studied in treatment protocols, fos-
tering active patient engagement (APE) and account-
ability, but whether these strategies result in improved
adherence remains to be determined. PAP devices have
the capability of displaying the previous night’s usage
and providing direct feedback. Cloud-based platforms
receive regular data updates from PAP machines and
allow for real-time monitoring of adherence by pro-
viders. Malhotra et al. compared APE technology, a
real-time internet-based patient engagement tool, to
usual care monitoring in a retrospective analysis of two
cloud-based databases (AirView and myAir).9 In
128 037 patients, APE was associated with more
patients achieving adherence deﬁned by US Medicare
criteria compared to usual care with remote monitoring
of PAP adherence (87.3% compared to 70.4%). Average
therapy usage was 5.9 h in the APE group versus 4.9 h
in the matched usual care group and patients ‘strug-
gling’ with CPAP therapy adherence had a 17.6% abso-
lute improvement in adherence using APE compared
with usual care.
Technological advances and the availability of wire-
less capabilities and cloud-based databases in transfer-
ring data have also placed sleep medicine in a unique
position for adopting telemedicine. Studies using tele-
medicine have shown mixed results on PAP
adherence.72–77 In a four-arm randomized, factorial
design clinical trial of 1455 patients referred for
suspected OSA (Tele-OSA), two telemedicine interven-
tions were implemented: (i) web-based OSA education
(Tel-Ed) and (ii) CPAP telemonitoring with automated
patient-messaging feedback (Tel-TM).73 Patients were
randomized to (i) usual care, (ii) Tel-Ed added,
(iii) Tel-TM added or (iv) Tel-Ed and Tel-TM (Tel-
both). Average daily CPAP use at 90 days was 3.8  2.5,
4.0  2.4, 4.4  2.2 and 4.8  2.3 h in usual care, Tel-
Ed, Tel-TM and Tel-both groups, respectively. Usage
was signiﬁcantly higher in the Tel-TM and Tel-both
groups versus usual care but not for Tel-Ed (P = 0.10).
Similar to prior studies on education, this study found
that even with a telemedicine platform, education
alone had no signiﬁcant inﬂuence on PAP use and it
again suggested that accountability may be more effec-
tive at inducing changes in adherence behaviour. Tele-
medicine was less expensive than standard
management, suggesting ongoing research on
advanced technologies in SDB should be encouraged.
Technological factors
Side effects are not uncommon with PAP (and oral
appliances) and technological advances are attempting
to address these side effects. Few added technological
features, however, have been shown to improve adher-
ence, and in fact while it seems intuitive, side effects
have not been shown to impact adherence signiﬁ-
cantly.7 Nonetheless, it is recommended that treatment
side effects be identiﬁed and addressed, including both
mask- and air pressure-related side effects.
Mask-related side effects include poor ﬁt with leak,
skin pressure and irritation, claustrophobia, dry mouth
and nasal congestion. It does not appear that the PAP
mask interface at treatment initiation signiﬁcantly inﬂu-
ences adherence but there are now a wide variety of
interfaces with few studies directly comparing them.7,78
Heated humidiﬁcation was developed to try to mini-
mize dryness but the evidence to date does not consis-
tently support improved adherence with the addition
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of this feature.79,80 Heated humidiﬁcation may reduce
symptoms of dry nose, mouth and throat, and should
be individualized. Condensation in the tubing or rain-
out can be minimized using heated tubing or tube
covers to reduce exposure of the tubing air to the
cooler surrounding environment.
Pressure-related discomfort has led to the develop-
ment of expiratory pressure relief technologies (e.g. C-
ﬂex in Respironics [Murrysville, Pennsylvania, USA],
EPR in Resmed [San Diego, California, USA]), which
reduces airway pressure during early expiration with a
return to the prescribed pressure at the end of expira-
tion to varying degrees. It too has not been shown to
improve adherence reliably.81–84 The ramp feature
reduces the initial PAP level, and then gradually
increases the pressure over a set time period to the
prescribed target, but no improvement in adherence
has been shown with the addition of the ramp. Again,
studies comparing auto-titrating units to traditional
CPAP units have shown similar adherence. In 62 OSA
patients randomized to CPAP or bilevel PAP, there was
no signiﬁcant difference between hourly use, the per-
centage of time that the device was running and the
prescribed pressure that was being delivered at 1 year.
Thus, bilevel PAP cannot be routinely recommended as
a strategy to improvement adherence in OSA.85
FUTURE DIRECTIONS
Our vision for the future is that patients would undergo
diagnostic testing using a wearable technology and/or
blood biomarker, and these data would be used to
assess disease severity and predict risk of complica-
tions. In some patients, administration of auto-titrating
PAP with follow-up as needed may be sufﬁcient. In
such cases, remote monitoring via cloud may be sufﬁ-
cient if patients were empowered to call for help when
needed. In other patients who may struggle with the
interface or other issues, troubleshooting could be
offered via telemedicine or face-to-face via a nurse
practitioner or respiratory therapist. This approach
would allow sleep specialists to focus on the most com-
plex patients who are struggling with therapy or who
have major co-morbidities that need to be addressed.
We strongly believe that innovative solutions using
technology to advantage will be required to deliver care
to the estimated 1 billion OSA patients worldwide.
More data are required to determine optimal manage-
ment of OSA.
CONCLUSION
Strategies are necessary to improve adherence to non-
surgical OSA treatment modalities, namely PAP. While
the current deﬁnition of adherence is mandated by
CMS to determine reimbursement, in the future
patients may beneﬁt from more individualized treat-
ment targets with the goal of reducing risk of OSA con-
sequences on a patient-to-patient basis. It seems clear
that certain patient characteristics (e.g. psychological
traits) and disease phenotypes (e.g. degree of EDS)
impact PAP adherence and as such are important
factors for the treating physician to note in assessing a
patient’s risk of non-adherence. In initiating treatment,
more support seems superior to less, and although
studies are difﬁcult to compare, OSA centres should
prioritize prescribing a support regimen based on avail-
able data and available resources early in the course of
a treatment trial. Development of new technologies,
speciﬁcally those that give direct patient feedback, is
ongoing and will hopefully improve adherence in moti-
vated patients. Overall, given a multitude of available
options with more in the pipeline, clinicians should be
optimistic about achieving adherence to OSA therapies
in their patients.
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